Biomarkers in Immunoglobulin Light Chain Amyloidosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F17%3A73591237" target="_blank" >RIV/61989592:15110/17:73591237 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/17:00098262 RIV/61988987:17110/17:A1801R4R RIV/00216208:11110/17:10365703 RIV/65269705:_____/17:00067299 a 2 dalších

Výsledek na webu

<a href="https://www.prolekare.cz/casopisy/klinicka-onkologie/2017-supplementum2-1/biomarkery-v-amyloidoze-lehkeho-retezce-imunoglobulinu-61621/download?hl=en" target="_blank" >https://www.prolekare.cz/casopisy/klinicka-onkologie/2017-supplementum2-1/biomarkery-v-amyloidoze-lehkeho-retezce-imunoglobulinu-61621/download?hl=en</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Biomarkers in Immunoglobulin Light Chain Amyloidosis

Popis výsledku v původním jazyce

Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.

Název v anglickém jazyce

Biomarkers in Immunoglobulin Light Chain Amyloidosis

Popis výsledku anglicky

Immunoglobulin light chain amyloidosis (AL amyloidosis - ALA) is a monoclonal gammopathy characterized by presence of aberrant plasma cells producing amyloidogenic immunoglobulin light chains. This leads to formation of amyloid fibrils in various organs and tissues, mainly in heart and kidney, and causes their dysfunction. As amyloid depositing in target organs is irreversible, there is a big effort to identify bio marker that could help to distinguish ALA from other monoclonal gammopathies in the early stages of disease, when amyloid deposits are not fatal yet. High throughput technologies bring new opportunities to modern cancer research as they enable to study disease within its complexity. Sophisticated methods such as next generation sequencing, gene expression profiling and circulating microRNA profiling are new approaches to study aberrant plasma cells from patients with light chain amyloidosis and related diseases. While generally known mutation in multiple myeloma patients (KRAS, NRAS, MYC, TP53) were not found in ALA, number of mutated genes is comparable. Transcriptome of ALA patients proves to be more similar to monoclonal gammopathy of undetermined significance patients, moreover level of circulating microRNA, that are known to correlate with heart damage, is increased in ALA patients, where heart damage in ALA typical symptom.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Klinicka Onkologie

ISSN

0862-495X

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

S2

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

"2S-60"-"2S-67"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85029484418